Healthcare & Life Sciences
InvAscent exits Anjan Drug Private Limited
About
Anjan Drug
Anjan Drug, established in 1990, manufactures APIs for CNS disorders such as anxiety, depression, epilepsy, schizophrenia, among others. Major products manufactured by Company include Valproic Acid, Sodium Valporate, Divalproic Sodium, Gabapentin & Magnesium Valporate with exports constituting over 80% of sales. The Company plans to launch at least 5 more products over the next 2 years across US, Latin America & Europe. Besides USFDA, the facilities are also inspected by EDQM, TGA, COFEPRIS and WHO GMP. Anjan enjoys a long standing relationship with its key clientele with a vintage of > 10 years with each of them.
Background
We are pleased to announce that the stake held by EILSF, a Private Equity fund advised by InvAscent (“InvAscent”) in Chennai head quartered Anjan Drug Private Limited (“Anjan”), has been acquired by a privately owned fine chemicals company.
Promoted by Mr. C. Kalaichelvan, Anjan has two USFDA inspected facilities manufacturing specialized API’s in the Central Nervous System (CNS) segment.
Anjan is the leader in the Valproates & value added salts in India and enjoys long standing marquee client relationships across Europe & the Americas including Abbot, Sanofi-Aventis, Teva, Mylan and Apotex. The Company is known for its green chemistry capabilities and process efficiencies which have delivered consistent growth and superior margins in the Industry.
“It has been an enriching experience to work with Invascent and their valuable inputs have helped us in our growth over the years. The VedaCorp team handheld us end-to-end through this investor exit process and their involvement has added substance to our next phase of growth. Thanks to VedaCorp team for their in-depth understanding of our requirements & superior support”
Mr. C. Kalaichelvan
Promoter, Anjan Drug Private Limited
“Promoted by first generation entrepreneur Mr. Kalaichelvan, Anjan’s uncompromising focus on ethical standards, corporate governance, process efficiencies and the ability to sustain operating margins in a tough pharma API market is commendable. Post the current transaction, the Company is well positioned for the next phase of growth & we believe they are poised to succeed in this endeavor”
Sivaraj Sekhar, Director
Director at Veda Corporate Advisors